Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1368
Shown on this page
12
Current sort
Recently updated
Campus scope
Stanford Medicine, Stanford & Palo Alto, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Stanford Medicine, Stanford & Palo Alto, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1033–1044 of 1,368 matching trials with a site at Stanford Medicine, Stanford & Palo Alto, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA), Intensive chemotherapy with 7 + 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Phase 3 Interventional

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

NCT03091660
Site status not listed — check the official record
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
174
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Phase 2 Interventional

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Selpercatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
306
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

NCT05130437
Status at this site: Recruiting
View directory record Official record
Conditions
Propionic Acidemia
Interventions
mRNA-3927
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
1 Year and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Not applicable Interventional

ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

NCT03319485
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson Disease
Interventions
ExAblate Pallidotomy, Sham ExAblate Pallidotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Stanford, California • Boynton Beach, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Not applicable Interventional

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

NCT00185744
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer, Carcinoma, Ductal
Interventions
Intra-Operative Radiotherapy (IORT), Lumpectomy, Whole Breast Radiotherapy, Intracavitary Brachytherapy, Accelerated External Beam 3-D Conformal Radiotherapy, Stereotactic APBI
Radiation · Procedure
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Phase 3 Interventional Results available

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

NCT04637594
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
377
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting No phase listed Observational

Heart Attack Research Program- Imaging Study

NCT02905357
Site status not listed — check the official record
View directory record Official record
Conditions
Myocardial Infarction
Interventions
OCT, CMR
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Phase 1 Interventional

FT819 in Subjects With B-cell Malignancies

NCT04629729
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
Interventions
FT819, Cyclophosphamide, Fludarabine, IL-2, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Davis, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions
Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
Drug · Radiation · Procedure + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Recruiting Not applicable Interventional

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

NCT06895070
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Transplant, Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 5, 2026, 9:55 AM EST
Recruiting Phase 1 Interventional

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
BMS-986453, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 5, 2026, 9:55 AM EST

About this Stanford Medicine institution page

What this page lists
ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.